JOHN SHUCK, M.D.; SHIAO SHEN, M.D.; LOREN OWENSBY, M.D.; MARTIN LEFTIK, M.D.; SAMUEL CUCINELL, M.D.
Spironolactone, a 17-spirolactone that competitively inhibits aldosterone, is used in treating secondary hyperaldosteronism (1) and is the preferred drug in treating primary hyperaldosteronism (2). Side effects include gastrointestinal, neurologic, dermatologic, and endocrinologic disturbances. Despite the frequent use of spironolactone in patients with liver disease, no liver toxicity has been reported. We report the case of a patient with primary hyperaldosteronism in whom hepatitis developed secondary to spironolactone therapy.
A 53-year-old woman presented in November with hypertension and hypokalemia. She had no medical history, took no medications, and drank no alcohol. Blood pressure was 220/100 mm Hg in both the
SHUCK J, SHEN S, OWENSBY L, LEFTIK M, CUCINELL S. Spironolactone Hepatitis in Primary Hyperaldosteronism. Ann Intern Med. ;95:708–710. doi: 10.7326/0003-4819-95-6-708
Download citation file:
Published: Ann Intern Med. 1981;95(6):708-710.
Adrenal Disorders, Endocrine and Metabolism, Endocrine Cancer, Gastroenterology/Hepatology, Hematology/Oncology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use